<DOC>
	<DOC>NCT00151749</DOC>
	<brief_summary>The purpose of the study is to see how safe and effective and tolerable the use of WelChol® is for type 2 diabetes when added to insulin alone or in combination with other anti-diabetic drugs</brief_summary>
	<brief_title>WelChol® and Insulin in Treating Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Colesevelam Hydrochloride</mesh_term>
	<criteria>Ages 18 75 years, inclusive Diagnosed with type 2 diabetes Stable insulin therapy for 6 weeks Stable dose of any other antidiabetic medications for 90 days Hemoglobin A1c value between 7.5% to 9.5% C peptide greater than 0.5 ng/mL Prescribed ADA diet History of type 1 diabetes or ketoacidosis History of pancreatitis Uncontrolled hypertension Allergy or toxic response to colesevelam or any of its components Serum LDLC less than 60 mg/dL Serum TG greater than 500 mg/dL Body mass index (BMI) greater than 45 kg/m2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Diabetes mellitus</keyword>
</DOC>